27306834|t|Naïve CD8(+) T cell derived tumor - specific cytotoxic effectors as a potential remedy for overcoming TGF-β immunosuppression in the tumor microenvironment
27306834|a|Despite of the potential implications for cancer immunotherapy, conventional approaches using in vitro expanded CD8(+) T cells have suboptimal outcomes, mostly due to loss of functionality from cellular exhaustion. We therefore investigated the phenotypic and functional differences among in vitro activated CD8(+) T cells of three different sources, namely naïve (NTeff), memory (MTeff) and tumor-infiltrating lymphocytes (TILeff) from human and mice, to better understand mechanisms behind potent effector functions and potential for overcoming current limitations. In line with the greater proliferation activity and longer telomere lengths of NTeff populations, cells of naïve origin exhibited significantly less amounts of T cell exhaustion markers than those of MTeff and TILeff, and moreover, acquired distinct expression patterns of memory-promoting transcription factors, T-bet and Eomes, induced in a rapid and sustainable manner. NTeff cells appeared to have lower expression of Foxp1 and were refractory to apoptosis upon TGF-β conditioning, implying better survival potential and resistance to tumor - induced immune suppression. Of CD8(+) T cell pools activated to tumor - specific CTLs, naïve cell generated effectors possessed the most potent cytotoxic activity, validating implications for use in rational design of adoptive immunotherapy.
27306834	0	5	Naïve	T017	UMLS:C3641721
27306834	6	19	CD8(+) T cell	T017	UMLS:C0242629
27306834	28	33	tumor	T038	UMLS:C0027651
27306834	45	64	cytotoxic effectors	T017	UMLS:C3641722
27306834	102	107	TGF-β	T103	UMLS:C0040690
27306834	108	125	immunosuppression	T038	UMLS:C4048329
27306834	198	218	cancer immunotherapy	T058	UMLS:C0278348
27306834	259	267	expanded	T082	UMLS:C0205229
27306834	268	282	CD8(+) T cells	T017	UMLS:C0242629
27306834	350	358	cellular	T017	UMLS:C0007634
27306834	464	478	CD8(+) T cells	T017	UMLS:C0242629
27306834	498	505	sources	T033	UMLS:C0449416
27306834	514	519	naïve	T017	UMLS:C3641721
27306834	521	526	NTeff	T017	UMLS:C3641721
27306834	529	535	memory	T017	UMLS:C0682639
27306834	537	542	MTeff	T017	UMLS:C0682639
27306834	548	578	tumor-infiltrating lymphocytes	T017	UMLS:C0079722
27306834	580	586	TILeff	T017	UMLS:C0079722
27306834	593	598	human	T204	UMLS:C0086418
27306834	603	607	mice	T204	UMLS:C0025929
27306834	655	663	effector	T017	UMLS:C3641722
27306834	749	762	proliferation	T038	UMLS:C0596873
27306834	783	791	telomere	T017	UMLS:C0085187
27306834	803	820	NTeff populations	T017	UMLS:C3641721
27306834	822	827	cells	T017	UMLS:C0007634
27306834	884	890	T cell	T017	UMLS:C0039194
27306834	902	909	markers	T201	UMLS:C0005516
27306834	924	929	MTeff	T017	UMLS:C0682639
27306834	934	940	TILeff	T017	UMLS:C0079722
27306834	974	993	expression patterns	T038	UMLS:C1171362
27306834	997	1035	memory-promoting transcription factors	T103	UMLS:C0040648
27306834	1037	1042	T-bet	T103	UMLS:C0913648
27306834	1047	1052	Eomes	T103	UMLS:C1454790
27306834	1097	1108	NTeff cells	T017	UMLS:C3641721
27306834	1132	1142	expression	T038	UMLS:C1171362
27306834	1146	1151	Foxp1	T103	UMLS:C3273485
27306834	1175	1184	apoptosis	T038	UMLS:C0162638
27306834	1190	1195	TGF-β	T103	UMLS:C0040690
27306834	1226	1234	survival	T038	UMLS:C0007620
27306834	1263	1268	tumor	T038	UMLS:C0027651
27306834	1279	1297	immune suppression	T038	UMLS:C4048329
27306834	1302	1315	CD8(+) T cell	T017	UMLS:C0242629
27306834	1335	1340	tumor	T038	UMLS:C0027651
27306834	1352	1356	CTLs	T017	UMLS:C0039195
27306834	1358	1368	naïve cell	T017	UMLS:C3641721
27306834	1379	1388	effectors	T017	UMLS:C3641722
27306834	1415	1433	cytotoxic activity	T033	UMLS:C0243095
27306834	1489	1511	adoptive immunotherapy	T058	UMLS:C0079613